Prilosec OTC taps two football stars for Living Proof campaign
CINCINNATI Procter & Gamble on Tuesday announced the signing of two NFL offensive linemen — New York Giants’ David Diehl and Minnesota Vikings’ Anthony Herrera — as spokesmen of the frequent-heartburn remedy Prilosec OTC. The two NFL players will be part of the Prilosec OTC Living Proof campaign to share their heartburn protection stories over the course of the 2010-2011 NFL season.
The Prilosec OTC Living Proof campaign will feature Diehl and Herrera’s stories about the importance of powerful protection on PrilosecOTC.com, and will be supported by television and digital advertising also featuring the players.
"David Diehl and Anthony Herrera are living proof that heartburn can happen to even the toughest people," stated Phil McWaters, Prilosec OTC brand manager. "These players will help people understand that frequent heartburn doesn’t have to get in the way of their daily activities and that Prilosec OTC can them help manage and protect against it."
CHPA names Melville its new president
WASHINGTON —Scott Melville has been named the new president of the Consumer Healthcare Products Association, succeeding Linda Suydam, who is retiring after eight years with CHPA. The news becomes official Nov. 1.
Prior to the announcement, Melville served as SVP government affairs and general counsel for the Healthcare Distribution Management Association. Before joining HDMA, Melville was as an attorney and head of government relations for Cephalon. A veteran facilitator, familiar with health care and the vital role over-the-counter medicines and natural products play in today’s healthcare system, Melville also is a former staffer for Rep. Jerry Lewis, R-Calif.
At CHPA, Melville will have an opportunity to bring all of his decades of experience as a healthcare sector advocate to bear. With healthcare reform on the line and millions of baby boomers hitting their 60s, CHPA chairman Christopher DeWolf said that Melville’s “experience in public policy, coalition building and working with government officials and key stakeholders will be invaluable in guiding the industry through the rapidly changing healthcare environment.”
Study: Consumers stay loyal to Tylenol, despite recent McNeil problems
PHILADELPHIA —According to a recent study released by the Relational Capital Group, consumer purchase intent and brand loyalty for Tylenol still is high despite the recent spate of Tylenol product recalls. According to the study, 76% of consumers reported positive purchase intent, and 67% reported positive brand loyalty for Tylenol.
That ought to be good news for Johnson & Johnson. During a hearing held earlier this month, J&J chairman and CEO Bill Weldon noted that McNeil Consumer would begin resupplying the recalled Tylenol products in the coming weeks and ramping up to traditional supply levels through first quarter 2011.
“As you look at the Tylenol situation, consumers are interpreting [McNeil’s] production problems as a short-term lapse in competence, rather than a significant change in what their intentions are toward consumers,” Chris Malone, chief advisory officer of the Relational Capital Group, told Drug Store News. “When we look at the Tylenol brand, it appears that there is such a long track record of reliability and trust, and a deep reservoir of good will,” he said, that consumers generally don’t believe J&J intentionally cut any corners in an effort to boost profits. In contrast, consumers generally identified both a lapse in competence and a dishonest pattern in the behavior of BP over the course of that company’s oil spill crisis.